HTx
Next Generation Health Technology Assessment
EU Horizon 2020 Project

Dalia Dawoud, PhD
Scientific Adviser
Science Policy and Research
National Institute for Health and Care Excellence (NICE)
United Kingdom

@drddawoud
https://www.linkedin.com/in/dalia-dawoud-8b2478159/
dalia.dawoud@nice.org.uk
Background

• **Aligning** health technology assessment (HTA) and clinical practice guidelines (CPG) recommendations is an **essential**, but **challenging**, task.

• **Consistent** and **coordinated** messages required now more than ever.

• **Processes**, as well as **outputs**, need to be harmonised.

• **It takes two to tango!**
Background

• **Priority** area for NICE as an organisation that produces both CPGs and TAs

• The **range and volume of our guidance** creates internal challenges in keeping it **up to date**, **aligning** our **work programmes** and data management, as well as the **efficient analysis and presentation of complex information**
NICE Connect
Reviewing how we produce and present guidance.
Advice and guidance integrated in a care pathway format – the ‘front door’

CHTE2020
Technology Appraisal Methods Review
Review of NICE methods for both technology appraisals (TAs) and highly specialised technologies (HSTs), including a review of the process of guidance production for HST.

https://www.nice.org.uk/about/who-we-are/nice-connect
https://tinyurl.com/y88sejh2
Science Policy and Research

HTx: Next Generation Health Technology Assessment
Horizon 2020 project funded by the European Union (2019-2023)

© The HTx Consortium 2019-2023. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 825162.

HTx 2nd General Assembly
Bern, 6-7 February 2020
Objectives

• To **create a framework for next generation HTA** that supports **patient-centered, societally oriented, real-time decision-making for integrated healthcare** throughout **Europe**.

• To **facilitate the development of methodologies** to deliver more **customized information** on the **effectiveness and cost-effectiveness of complex and personalised combinations** of health technologies.

• To **provide methods to support personalised treatment advice** that will be shared with **patients and their physicians**
Structure

WP1: Treatment pathways, therapeutic areas
- Define Framework
- Case 1
- Case 2
- Case 3
- Generalise Cases

WP2: RWD Evidence Synthesis

WP3: AI Treatment Prediction

WP4: Implementation, system and processes
- PROMS SDM
- Synergies
- INT. Consensus
- Payment Funding
- Policy Sandbox

WP5: Transferability and Dissemination

WP6: Scientific Coordination and Project Management

Scientific Coordination and Project Management

Expert Forum

HTx Forum

© The HTx Consortium 2019-2023. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825162.
Objectives- WP4

Implementation into systems and processes

• International consensus building on the HTx methods. That will include building consensus between HTA organisations in Europe and between HTA organisations, regulators and guideline developing organisations.

• To increase patient-centricity in decision-making.

• To support development of flexible funding and reimbursement models for complex health technologies. This also includes assessment of the transferability of these models throughout Europe
Methodology

1. Descriptive study
   a. HTA organisations
   b. CPG developers

2. Document review
1. Descriptive study

• Aim
  • to explore the currently existing synergies after marketing approval, between HTA agencies and clinical guideline development (both formal in person collaborations and utilisation of documents developed by both parties).
  • To identify critical aspects where further improvement in synergies is needed.

• Methods
  • Online questionnaire
  • Face-to-face (virtual?) workshop
Questionnaire development and administration

- **Background**
  - Literature
  - Experts

- **Conceptualisation**
  - Collaboration
  - Regular TCs

- **Format**
  - Online

- **Validity**
  - Expert Readability
  - Pilot testing

- **Reliability**
  - Pilot testing
Questionnaire development and administration

- Experience in HTx case study areas
- Formal and informal collaboration with CPG developers
- Benefits and Challenges of closer working
- Information needs
Questionnaire development and administration

<table>
<thead>
<tr>
<th>Dissemination</th>
<th>Communication</th>
<th>Data analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 East + West EU countries</td>
<td>Announcements</td>
<td>Ongoing</td>
</tr>
<tr>
<td>EUnetHTA partners</td>
<td>Reminders</td>
<td>LimeSurvey tools</td>
</tr>
</tbody>
</table>

21 HTA organisations completed the questionnaire
2. Document Review

• Aim
  • To investigate whether recommendations from 6 European HTA organisations in published documents, are in line with the recommendations in CPG documents.

• Multiple sclerosis will be used as a case study for the analysis
Next Steps

- **CPG developers** to receive the questionnaire later this year.
  - Please, take time to complete it

- Joint **face-to-face/virtual workshop** for HTA organisations and CPG developers
Acknowledgements

- Milou Hogervorst
- Wim Goettsch
- Diana Delonij
- Ayla Lokhorst
- Emily Leckenby
- Páll Jónsson
- HTx WP4 Team
- HTx Consortium Partners
Thank You!

Website: [www.htx-h2020.eu](http://www.htx-h2020.eu)
E-mail: [info@htx-h2020.eu](mailto:info@htx-h2020.eu)

@htx_h2020

https://www.linkedin.com/company/htx-h2020/